pharmaphorum

NOVEMBER 14, 2022

Sales of Dupixent rocketed 45% to around $2.4 Dupixent was cleared by the US FDA for adults with PN in September, making it an option for an estimated 75,000 patients with the condition, and adding to the drug’s earlier approvals in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic oesophagitis.

Sales 118

Sales Immune Response Drugs Medicine 118

The Pharma Data

DECEMBER 29, 2020

As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. Regeneron Pharmaceuticals, Inc. futility analysis). The results passed the futility analysis (p<0.3

Antibody 52

Antibody Trials Production Clinical Trials 52

pharmaphorum

FEBRUARY 10, 2022

In its annual results statement, AZ said that it took the decision on the back of data showing that a third dose of Vaxzevria increased the immune response to new variants, including Omicron which is currently driving new COVID-19 cases around the world. ” Vaxzevria added almost $4 billion to its revenues last year, including $1.8

Vaccination 52

Vaccination Vaccine Development Immune Response 52

pharmaphorum

JULY 14, 2021

The bulk of Prevnar 13 sales come from use in adults, and with Merck & Co in the final stages of regulatory review of its rival vaccine V114 – covering 15 serotypes and filed for adult use – the franchise is facing some serious competition for the first time. That is equivalent to 14% of Pfizer’s total revenues.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

The Pharma Data

NOVEMBER 20, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Production Clinical Trials Clinical Trials 52

pharmaphorum

MARCH 28, 2022

GlaxoSmithKline and Vir’s Xevudy has become the latest COVID-19 antibody therapy to have its use restricted by the FDA as a result of waning activity against new variants of the virus. The antibody made a substantial contribution to GSK’s top-line last year, adding around $1.25 2 subvariant of Omicron.

Antibody 52

Antibody Immune Response Regulation Sales 52

pharmaphorum

SEPTEMBER 2, 2020

The drug, JTX-1811, is a monoclonal antibody designed to selectively deplete immunosuppressive tumour-infiltrating T regulatory (TITR) cells. . When JTX-1811 binds to CCR8, it targets TITR cells for depletion by an enhanced antibody-dependent cellular cytotoxicity mechanism. .

Licensing 71

Licensing Licensing Antibody Immune Response 71

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

pharmaphorum

MAY 31, 2022

billion in sales last year. The pandemic and the timing of US government purchases for immunisation campaigns trimmed back sales from almost $5.9 The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot.

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

pharmaphorum

DECEMBER 21, 2020

Each programme includes undisclosed upfront and milestone payments plus royalties on sales, with Merck indicating in a statement that it will be funding the research. billion alliance with Taiho and Astex for cancer antibodies, including a KRAS drug, and a $4.2 Other recent deals include a $2.8 Other recent deals include a $2.8

Immune Response 59

Immune Response Sales Antibody Drugs 59

XTalks

NOVEMBER 15, 2023

Valneva recently reported that it has been experiencing an increase in sales of its other vaccines due to the “recovery of the travel industry.” It appears the company has already done so as its quarterly earnings report included $96 million and $117 million of additional revenue from the sale of the PRV in its 2023 revenue guidance.

FDA Approval 59

FDA Approval Vaccination Vaccine In-Vitro 59

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

pharmaphorum

SEPTEMBER 20, 2022

Though there is little question that sales generated in the area will come back to earth in the years to come, the industry’s outlook on the potential of vaccines and the infectious diseases area has been permanently shifted. This all comes down to the impact of the pandemic. Boosting vaccine equity.

Vaccination 98

Vaccination Vaccine Immune Response Antibody 98

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain.

Drugs 69

Drugs Immune Response Allergies Sales 69

The Pharma Data

NOVEMBER 21, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. government allocation program. Regeneron Pharmaceuticals, Inc.

Antibody 40

Antibody Production Clinical Trials Clinical Trials 40

The Pharma Data

JANUARY 22, 2021

An Ohio State University review of 49 vaccine studies dating back 30 years examined how stress, depression and healthy behaviors, such as exercise, can affect immune response to a vaccine. “What we see is that stress can delay your antibody response to the vaccine,” Kiecolt-Glaser said.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

pharmaphorum

FEBRUARY 9, 2022

Closely related to this is the fact that global spending on oncology drugs reached $164 billion in 2020, with drug sales growing at a compound annual growth rate of 14.3% While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response.

Vaccination 134

Vaccination Vaccine Clinical Trials Clinical Trials 134

XTalks

JULY 8, 2021

The drugs are monoclonal antibodies against the IL-6 receptor. Patients with severe COVID-19 often have an overactivation of the immune system, which involves the increased release of cytokines (cytokine release syndrome) such as IL-6. By blocking the cytokine from binding to its receptor, the hyperactive immune response can be tamed.

Doctors 94

Doctors Doctor Manufacturing Drugs 94

The Pharma Data

JUNE 30, 2021

Yasmin Parr’s study of FeLV shows that the outcome of FeLV infection is influenced by the host immune response, with progressively infected cats, so cats whose conditions are worsening, having weaker immune responses. “In billion euros in 2020 and presence in more than 150 countries.

Scientist 52

Scientist Immune Response Antibody Development 52

The Pharma Data

NOVEMBER 17, 2020

t for the treatment of autoimmune diseases , which occur when the body’s immune system attacks its own cells and tissues as foreign invaders. . While the antibody responsible for immune-mediated diseases is yet to be identified, they are thought to be regulated by an aberrant immune response. Source link.

Immune Response 52

Immune Response Licensing Licensing Sales 52

pharmaphorum

JANUARY 4, 2023

They both also include tiered royalties on sales of any products emerging from the partnerships. The hypothesis is that it will induce immune tolerance by stimulating anti-inflammatory regulatory T- (Treg) cells and cytokines that dampen down the immune response.

Immune Response 52

Immune Response Engineer Licensing Licensing 52

pharmaphorum

FEBRUARY 14, 2022

billion in sales last year, slightly down as a result of the pandemic. Like Shingrix, CRV-101 is a subunit vaccine based on the glycoprotein E (gE) antigen of the herpes zoster virus, delivered alongside an adjuvant to boost the immune response.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

The Pharma Data

JANUARY 12, 2021

The novel immune checkpoint inhibitor Sanofi deemed worthy of such an investment is BND-22, a humanized IgG4 antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor, an inhibitory receptor expressed on both innate and adaptive immune cells. It is being developed for the treatment of solid tumors.

Immune Response 52

Immune Response Clinical Trials Clinical Trials Development 52

XTalks

MAY 2, 2024

The firm predicts sales of KarXT could reach $2.8 Current drugs on the market for schizophrenia include Lundbeck and Otsuka’s Rexulti (brexpiprazole) and Eli Lilly’s Prozac (fluoxetine), but these drugs derive the majority of their sales from other conditions, including severe forms of depression or Alzheimer’s agitation. billion ($1.5

Drugs 52

Drugs FDA Approval Vaccination Vaccine 52

Delveinsight

SEPTEMBER 8, 2021

Benlysta Sales and Annual cost of therapy (ACOT). As per DelveInsight’s report on Benlysta (Belimumab) market forecast , the sale of Belimumab has kept on increasing year after year. In 2017, the total sale of Belimumab was USD 119 million across all three regions (the United States, Europe, and International).

Marketing 52

Marketing Sales FDA Approval Antibody 52

XTalks

OCTOBER 25, 2022

Imjudo is an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody that blocks the action of CTLA-4. Inhibition of the protein aids in T-cell activation to prime the immune system against cancer cells to induce their death. billion in 2020, an increase of 20 percent.

FDA Approval 94

FDA Approval Trials Drugs Immune Response 94

pharmaphorum

AUGUST 16, 2020

The fund has already been deployed to order Gilead’s antiviral drug Veklury (remdesivir) and apheresis equipment to collect antibodies from the blood of patients who have recovered from COVID-19.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

The Pharma Data

OCTOBER 9, 2021

years of exposure 3 Design of a new open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in MS-patients treated with Kesimpta 4 , and new findings from open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in secondary progressive MS (SPMS) patients treated with Mayzent will be presented 5.

Immune Response 52

Immune Response Vaccine Vaccination Medicine 52

XTalks

JULY 8, 2021

The drugs are monoclonal antibodies against the IL-6 receptor. Patients with severe COVID-19 often have an overactivation of the immune system, which involves the increased release of cytokines (cytokine release syndrome) such as IL-6. By blocking the cytokine from binding to its receptor, the hyperactive immune response can be tamed.

Doctors 52

Doctors Doctor Manufacturing Drugs 52

The Pharma Data

AUGUST 22, 2021

AZD7442 is the first antibody combination (non-vaccine) modified to potentially provide long-lasting protection that has demonstrated prevention of COVID-19 in a clinical trial. More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination.

Trials 52

Trials Antibody Vaccination Vaccine 52

The Pharma Data

APRIL 27, 2021

Q1 2021 sales increase of 2.4% Specialty Care sales grew 15.3%, due to strong Dupixent ® performance (+45.6% General Medicines core assets grew 4.4%, while GBU sales were down 3.8%. Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. IFRS net sales reported.

Sales 52

Sales Vaccination Vaccine Medicine 52

The Pharma Data

JUNE 2, 2022

” In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. New GSK reaffirms its full-year 2022 guidance and the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

MAY 31, 2022

In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. New GSK reaffirms its full-year 2022 guidance and the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Delveinsight

AUGUST 26, 2021

Under the agreement, Shape is eligible to receive an initial payment and payments for hitting development, regulatory and sales milestones potentially exceeding USD 3 billion in aggregate value. Researchers will compare the two-time points to recognize the optimum timing of peak immune response following nasal vaccination.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

XTalks

MARCH 8, 2024

According to Amgen’s last earnings report , Prolia sales increased 12 percent last year to more than $4 billion, and Xgeva’s jumped five percent from last year to $2.1 Denosumab is a RANKL (receptor activator of nuclear factor kappa beta ligand) monoclonal antibody that blocks the ability of RANKL to bind to its receptor RANK.

Drugs 59

Drugs FDA Approval Production Immune Response 59

XTalks

MAY 1, 2023

At its peak sales, Qalsody is expected to generate around $300 million for Biogen. Tegoprubart is an anti-CD40L antibody designed to inhibit the CD40 and CD11 costimulatory signaling pathways. Developed by Eisai and Biogen, Leqembi is an amyloid beta-directed antibody.

FDA Approval 62

FDA Approval Gene Genetics Protein 62

The Pharma Data

DECEMBER 23, 2020

Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0 mg and 2.0 The 1.0

DNA 40

DNA Vaccination Vaccine Immune Response 40